Novo Nordisk’s insulin manufacturing facility in Boufarik (province of Blida) will start production in August 2019 after the completion of buildings and laboratories, and the settlement of some constraints, the project’s manager announced Tuesday.
He stressed that this commissioning will take place “as soon as the completion of the works of the buildings and laboratories, currently being finished, in addition to solving the outstanding problems,” he added.
According to the manager, the project is facing a number of constraints related to the refusal of some traders to release a portion of the base for the implementation of a parking, a land currently exploited by them at the Boufarik wholesale market, which makes access to the plant difficult, during the weekly market days (Monday and Thursday), he explained, calling local authorities to help him in the settlement of the problem of the land intended for the extension of this factory.
He also deplored the inadequacy of water and electricity for the needs of the project, in addition to the problem of importing certain components of the testing machines.
The wali, for his part, invited the managers in charge of the project to meet, in the coming days, with the managers of all the concerned sectors, in order to find adequate solutions to all the posed problems.